There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cormedix (CRMD – Research Report) and SCYNEXIS (SCYX – Research Report) with bullish sentiments.
Cormedix (CRMD)
In a report released today, Serge Belanger from Needham maintained a Buy rating on Cormedix, with a price target of $10.00. The company’s shares closed last Friday at $5.26.
According to TipRanks.com, Belanger is a 3-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cormedix with a $12.67 average price target, a 134.6% upside from current levels. In a report released today, Truist Financial also maintained a Buy rating on the stock.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CRMD:
- CorMedix Inc. to Participate in Two Upcoming Investor Conferences
- CorMedix expects cash to fund operations for at least 12 months
- CorMedix reports Q1 EPS (25c), consensus (28c)
- CorMedix Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
- CRMD Earnings this Week: How Will it Perform?
